Slidesets Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis Slidesets Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results Slidesets REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis Slidesets Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML Slidesets Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS Slidesets Retrospective Analysis for Validation of 2022 WHO and ICC Classification Systems for Patients With Myelodysplastic Syndromes Slidesets MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi Slidesets Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF Slidesets JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET Slidesets STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS